Expanded capabilities support development and production of novel functional lipid excipients and nanoparticle formulation Addition of late stage clinical and commercial-scale production is also planned Company to present on shielding lipid novel excipients for lipid nanoparticle (LNP) formulations at Lipid Nanoparticles Development Summit on October 20th Valencia, Spain and Boston,
PaternaMajor and the Spanish Government Innovation Delegation identified Curapath (formerly PTS), as one of the most innovative companies in the Valencian Community region. The Government delegate in the Valencian Community, Pilar Bernabe, visited the Paterna Technology Park, an area that has a number of high-tech industries, research centers and significant focus
Curapath, (formerly PTS) a leader in the custom design, development, and end-to-end GMP manufacture of polymer and lipid-based drug delivery systems is partnering with the organizers of the LNP Development Europe Summit. Dr. Vicent Nebot, CTO of Curapath, will be delivering a talk entitled “Development of Shielding Lipid Novel Excipients for
Hipra Scientific S.L.U, Polypeptide Therapeutic Solutions S.L., Biotechvana S.L. y Nostrum Biodiscovery constituyen el consorcio de empresas que participan en el proyecto “Investigación de una nueva vacuna para una enfermedad respiratoria humana”, subvencionado por el CDTI (Centro para el Desarrollo Tecnológico Industrial), apoyado por el Ministerio de Ciencia e Innovación
